Cyprotex Share Discussion Threads

[buywell2] 31/3/2015 07:17

Re todays RNS ... a very timely development methinks


High Throughput Screening (HTS) Market worth $19,626.54 Million by 2018

According to the new market research report the “High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.



Browse 75 tables and 23 figures spread through 245 pages and in-depth TOC on "High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018"
hxxp://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html
Early buyers will receive 10% customization on reports.

This report studies the global high throughput screening (HTS) market over the forecast period of 2013 to 2018. The global HTS market was valued at an estimated $13,735.88 million in 2013 and is poised to grow at a CAGR of 7.4% from 2013 to 2018, to reach $19,626.54 million by 2018.

A number of factors such as technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in the HTS technology by organizations are driving the growth of the HTS market. Moreover, the presence of a large untapped market in emerging countries and the incessant rise in outsourced drug discovery services especially in China and India are the various growth opportunities in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors that are curbing the growth of this market.

The HTS market is broadly classified into five segments, namely, technology, products, applications, end users, and geography. In the applications segment, the target identification market held the largest share of 45% in 2013. The availability of large compound libraries and well-equipped HTS laboratories, and technological advancements are the major factors driving the growth of this market. However, the primary screening market is poised to grow at the highest CAGR. The availability of a large number of potential lead compounds, emergence of several new detection technologies, and availability of novel primary and stem cell phenotypes are the factors that are responsible for the growth of this market segment. The growth in the outsourcing of drug services, especially in the Asian region, is a major reason for the high growth of the HTS market. In the end-users market, the pharmaceuticals segment dominated the market in 2013, with a market share of around 45%. In the technology market, the label-free technology segment is expected to register the highest growth in the forecast period. Label-free technology offers the direct detection ability, which was not possible with cell-based assays. Furthermore, it helps in reducing drug failure due to toxicity and can be applied to a majority of drug classes.

The global HTS market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The large market share of the North American region is attributed to the increased investments by drug discovery firms for the promotion and advancement of technologies and increasing number of collaborations among companies and academia to develop and distribute innovative HTS products.

The major players in the HTS market include Agilent Technologies (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.), and Tecan group (Switzerland), among others.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: [phone]
Email: [e-mail]

[buywell2] 31/3/2015 07:14

............ Cyprotex PLC Launch of new HTS laboratory in its US facility ............

31 March 2015

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex launches new high throughput screening laboratory in its US facility

31st March, 2015; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announced today the launch of a new high throughput screening laboratory at its US facility in Watertown near Boston. The laboratory replicates the highly successful ADME screening laboratory in Cyprotex's UK facility which has been developed in-house over the past 16 years using the combined expertise of our skilled software engineers and scientists. The unique platform allows Cyprotex to provide services which generate high quality consistent data in a rapid and cost-effective manner. All our customers, large and small, have access to and can benefit from the services available in North America.

The new facility houses state of the art automated liquid handling instruments and LC-MS/MS analytical instruments as well as a team of scientists and software engineers who are experienced in the field of high throughput screening. The integration has been led by our UK team who have been responsible for training staff and managing the smooth transfer of existing procedures and cross validation of the assays.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: "Expansion of our high throughput screening facility to the US has always been a much desired part of our growth strategy plans. Our unique software platform combined with state of the art automation and bioanalytical capabilities make us one of the only contract research facilities to be able to screen such large numbers of compounds in such a wide range of assays with relative ease. The medium and large Pharmaceutical companies who require high capacity and high quality screening with short turnaround times are realising the benefit of working with Cyprotex and as such the number of strategic deals are increasing and are a key factor in the growth of our business.



buywell2 says

Todays RNS is a great step forwards as HTS is a growth area.

Cyprotex now have the equipment, technology and trained staff to be able to tender for much larger volume contracts that require these three components in order to satisfy clients demands in terms of speed of delivery and quality of data provided and to satisfy existing USA contracts with the EPA (Environmental Protection Agency ) which could soon increase in size of chemical compounds tested ( contracts for the numbers have already been signed but the EPA has not yet fully pulled the trigger on the numbers tested as yet ) .

Things are now in place for larger contracts to be won.

2015 turnover looks set to improve as a result of this RNS

[buywell2] 30/3/2015 20:32

Cyprotex have been very busy in the USA the other week


Cyprotex - The ADME-Tox Specialists
Society of Toxicology Annual Meeting , San Diego, CA  

March 22 - 26, 2015


In conjunction with the Society of Toxicology annual meeting, Cyprotex is excited to announce several exciting new research developments.

Come see us at Booth 1733 or email us to schedule a time to meet.

Exhibitor-Sponsored Session
Utilization of In Vitro Mechanistic and 3D Models to Improve the Prediction of Hepatotoxicity and Cardiotoxicity
Presented by: Clive Dilworth, PhD, Cyprotex
Monday, March 23
10:45 am - 11:45 am
Room 24B

This presentation will cover recent developments in the field of in vitro prediction of cardiotoxicity and hepatotoxicity.
It will focus on the development of 3D cell-based cardiac and hepatic systems and their applicability in mechanistic mitochondrial assays (Seahorse XFe96 flux analyser) and 3D high-content imaging.

Poster Presentations

A High-Throughput MEA Assay Utilizing Rat Cortical Neurons Can Detect Both Glycine Receptor and GABAA Receptor Seizure Responses in Brucine
Presented by: Christopher Strock, PhD, Cyprotex US
Monday, March 23
9:30 am - 12:30 pm
Abstract Number 280
Poster Board 451
CC Exhibit Hall

Attrition due to neurotoxicity is a significant issue in drug discovery because current assays cannot accurately predict sublethal target-specific electrophysiological liabilities. We have developed a high-throughput assay that combines microelectrode array (MEA) technology, custom algorithms and Matlab scripts to accurately screen for neurotoxic liabilities using spike data from cryogenically preserved rat cortical neurons.
This assay distinguishes proconvulsant mechanisms and resolves two separate mechanisms in one compound to serve as a powerful characterizer of neurotoxic responses.


Statistical Modeling of DILI Prediction for a Multiplexed HCS Toxicity Assay
Presented by: Christopher Strock, PhD, Cyprotex US
Tuesday, March 24
1:00 pm - 4:30 pm
Abstract Number 1323
Poster Board 220
CC Exhibit Hall

The challenge of high content screening (HCS) assays has been interpreting data for predicting the true toxic liabilities of compounds. By utilizing compounds contained in the US FDA's Liver Toxicity Knowledge Base (LTKB), we implemented a machine learning approach to construct classifiers of toxic liability. We have also developed a new algorithm for ranking compounds with unknown exposure with estimation of a Cmax threshold of toxicity using a probability of class membership.


Evaluation of an In Vitro Human Dermal Sensitization Test for Use with Medical Device Extracts
Presented by: Jamin Willoughby, PhD, Cyprotex US, Kelly Coleman, PhD, Medtronic
Wednesday, March 25
9:00 am - 12:30 pm
Abstract Number 2015
Poster Board 656
CC Exhibit Hall

The guinea pig maximization test (GMPT) required by ISO 10993-10 to assess dermal sensitization for medical device biocompatibility is time consuming and expensive. By utilizing EpiDerm™ 3D skin tissues from MatTek and the SenCeeTox® assay which monitors specific genes controlled by Nrf2/ARE, we successfully identified 80% of test samples positively or negatively as skin sensitizers. Additionally, about 50% of the potencies showed accurate concordance with in vivo data.


Development, Optimization, and Standardization of an In Vitro Skin Irritation Test for Medical Devices Using the Reconstructed Human Tissue Model EpiDerm
Presented by: Helena Kandarova, PhD, MatTek, Jamin Willoughby, PhD, Cyprotex US
Wednesday, March 25
9:00 am - 12:30 pm
Abstract Number 2017
Poster Board 658
CC Exhibit Hall

Assessing dermal irritation potential is an important part of medical device development. However, reconstructed human epidermis (RhE) models don't always meet the needs of ISO 10993 because medical device extracts are often dilute solutions with low irritation potential. In 2013 a protocol was optimized using known irritants, and in 2014 nine EU and USA laboratories were trained in the use of a standardized protocol. All laboratories produced data with nearly 100% agreement of predictions, indicating that modified skin irritation test has to potential to assess skin irritation by medical devices.


Improved Detection of Mitochondrial Toxicants Using Oxygen Consumption and Extracellular Acidification Rate in Comparison to the Glu/Gal Assay
Presented by: Paul Walker, PhD, Cyprotex
Thursday, March 26
8:30 am - 12:00 noon
Abstract Number 2672
Poster Board 418
CC Sails Pavilion

Mitochondrial dysfunction has been implicated in numerous drug induced adverse events, such as liver failure and cardiac toxicity. Using the XFe96 flux analyser (Seahorse Biosciences) and the mitochondrial stress test, it is possible to assess basal oxygen consumption rate (OCR), proton leak, ATP turnover, maximal respiration, reserve capacity and non-mitochondrial OCR whilst simultaneously, measuring extracellular acidification rate (ECAR) as a marker of glycolysis.


Combination of Cheminformatics and In Vitro Assays to Predict Skin Sensitization Potential and Potency
Presented by: Jamin Willoughby, PhD, Cyprotex US
Thursday, March 26
8:30 am - 12:00 noon
Abstract Number 2479
Poster Board 111
CC Sails Pavilion

Skin sensitization is a complex biological process of interactions of several cell types, proteins and molecular events that results in the development of allergic contact dermatitis. By using in silico and in vitro methods in tandem, we have been able to show predictivity of 95% sensitivity and 84% specificity with 86% accuracy.

[p1nkfish] 30/3/2015 17:47

From the Instem results today, partly applies to CRX too. I hold Instem as part beneficiary of need to speed cost-effective drug approvals.

"Total research and development pipelines within the pharma sector have increased by almost 9% to approximately 12,300 drug candidates during 2014, which makes us particularly positive about our outlook for the future as we can now see sustainable growth across our target markets," said Chief Executive Officer Phil Reason in a statement.

[buywell2] 30/3/2015 08:02

In connection with the 12th March RNS

The Drug Interactions data below is from 2008 .... so actual numbers of 1 in 25 over 57 year olds being ''at risk '' is now most likely worse

50% of over 57 year olds take AT LEAST 5 medical products

medical product = A prescription drug from the doctor, or An 'over the counter' OTC purchase from local chemist , or a health supplement eg multi vitamin tablet





Drug Interactions
- One Survey
• National survey of 3005 community- residing older adults (>57 YO) in US
• 80% of individuals takes > 1 medical product (prescription, OTC, supplement)
• 50% takes at least 5 medical products
• 30% takes at least 5 prescription drugs

 1/25 at risk of major drug-drug interaction


March 7, 2015

click the 2 links




Drug Interaction Presentations

2015

•When should in vivo transporter-mediated drug-drug interaction studies be conducted? A scientific perspective. (PDF -1.4MB)
Lei Zhang, Ph.D., Office of Clinical Pharmacology, OTS, CDER, FDA
American Society for Clinical Pharmacology (ASCPT) Annual Meeting, New Orleans, LA ; March 7, 2015


•Drug Interactions - An Evolution in Drug Development (PDF - 3.15MB)
Shiew-Mei Huang, Ph.D.; Deputy Director, Office of Clinical Pharmacology, OTS, CDER, FDA
American Society for Clinical Pharmacology (ASCPT) Annual Meeting, New Orleans, LA; March 7, 2015

[bigman] 27/3/2015 20:52

Bit out of touch with this since I sold out, maybe time to get back in at this low price ( compared to 120p I sold at) Admit I was very lucky to get that price. But could not resit 50k+ profit.
Can anyone tell me when results due as last year and before it was this week and cant find an announcement ?
Same with brokers forecast, can anyone post that ?
Am sure buywell will have your finger tips
Thanks

[bigman] 26/3/2015 08:46

Bit out of touch with this since I sold out, maybe time to get back in at this low price ( compared to 120p I sold at) Admit I was very lucky to get that price. But could not resit 50k+ profit.
Can anyone tell me when results due as last year and before it was this week and cant find an announcement ?
Same with brokers forecast, can anyone post that ?
Am sure buywell will have your finger tips
Thanks

[p1nkfish] 25/3/2015 07:56

they need to go further and there be a global standard.
the change they have made is as much to help their indigenous manufacturers as much as for any other reason.

[buywell2] 24/3/2015 07:35

It’s Official! China Ends Mandatory Animal Testing for Cosmetics



July 3, 2014

Animal advocates are celebrating another victory for animals in labs following the announcement that as of this week, China will no longer require animal testing for some types of cosmetics products manufactured in the country.

As of Monday, the China Food and Drug Administration (CFDA) stopped requiring tests for ordinary cosmetics, including make-up, skin, hair and nail care products and fragrances that are produced in the country and will instead allow manufacturers to choose available alternatives to conduct risk assessments.

“This is an important first step for China in moving away from cruel and unreliable animal testing for cosmetics. Our Be Cruelty-Free campaign has worked hard to achieve this milestone, but we know much work remains before we eliminate all cosmetics animal testing in China, so we are not resting on our laurels. In making this rule change, China is acknowledging the global trend towards cruelty-free cosmetics, and that’s hugely significant,” Peter Li, PhD, Humane Society International’s China policy adviser, said in a statement.

HSI estimates that as many as 300,000 rabbits, guinea-pigs, mice and other animals are used to test cosmetics in the country annually and that if every eligible company that can chooses to take advantage of this change in policy an estimated 10,000 animals could be spared from cruel and unnecessary tests every year.

China’s mandatory testing requirement hasn’t just caused unnecessary suffering for animals, but has shut companies that refuse to test on animals out of the market. It has also caused problems for companies that claim they don’t test on animals, but still sell in China, including Avon, Mary Kay and Estée Lauder, which has also led to confusion and anger for consumers who want to buy cruelty-free products and were led to believe they were.

While the new rule doesn’t apply to imported cosmetics or other types of personal care items, such as hair dye, deodorant and sun screen, animal advocates are hoping that this change represents a growing shift away from using animals and that it will be the first of more victories to come on the road to a cruelty-free world.

This weekend, HSI and more than 20 Chinese animal advocacy organizations welcomed the news in a letter to the CFDA and are now urging the agency to go further to stop animal testing in China.

While we celebrate China’s regulatory change, we also hope very much that China will go further and next apply the removal of mandatory animal testing to foreign-imported cosmetics too, as well as replace post-market animal testing with in vitro-based safety tests. In doing so, China would establish itself as a major cruelty-free cosmetics producer and market, with cruelty-free brands from around the world bringing their beauty products to Chinese consumers, and Chinese cruelty-free products expanding to international markets. It would also see China well placed to take a leading role in the manufacture and development of high-tech non-animal research tools.

Meanwhile, animal advocates are continuing to push for more countries to ban the practice. While the European Union and a few other countries, including Israel and India, have bans in place many others still allow it, including the U.S.

Now there’s hope that the U.S. could join others that have stopped the practice. In March, the Humane Cosmetics Act was introduced, which if passed would make it illegal to conduct or commission animal testing for cosmetics after a phase in period. With the availability of data on thousands of ingredients we already know are safe and the growing demand for cruelty-free products there’s no reason not to stop the practice here.

[p1nkfish] 23/3/2015 22:50

To make a difference it needs the Chinese to act as I am suspicious some manufacturers animal test to get into China (mandatory) and use results elsewhere.

[buywell2] 23/3/2015 11:17

Regarding the latest RNS on 19th March

Following on from the banning of animal testing within the Cosmetics Industry in the EU and several othet countries and growing

Another development re the banning of animals in another industry ..... see piece at bottom


This change re the use of animals particularly for acute toxicity testing ..... (where they are killed to ascertain the 'death' dosage of a chemical/drug/product under test .... eg cosmetic item such as lipstick , face cream etc )

Which has been going on for OVER 50 years and has spawned a $ BILLION dollar industry in animal testing provision in itself is at last under scrutiny as the public and animal charities force politicians and companies to rethink what they are doing

The tens of $ Billions paid out in lawsuits due to deaths and drug induced injuries in humans on animal tested drugs , chemicals and products is also no doubt focussing the accountants attention on the issue.











UK Home Office bans Animal Testing of Household Products
March 23rd 2015

UK Home Office bans Animal Testing of Household Products

The Rt Hon Lynne Featherstone MP announced on Thursday 12th March 2015 that the UK will ban testing of households products on animals. The ban will come into force in October 2015 and will cover all finished products including detergents, polishes and cleaning products, laundry products, air fresheners, deodorants, paints and other decorating materials. The testing requirements only apply to ingredients which make up >50% of the finished household product. Although the ban is a welcome first step to reducing animal testing, campaign groups feel the regulation should be stricter and apply to any ingredients within household products.

The full announcement can be found on the UK Government website:



To address the new regulations, Cyprotex offer a range of skin and ocular methods as in vitro alternative tests for assessing potential toxicity of household products.

[p1nkfish] 19/3/2015 12:54

CRX should get some of this.
£6m total.

[buywell2] 15/3/2015 12:23

High Throughput Screening (HTS) Market worth $19,626.54 Million by 2018

According to the new market research report the “High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.



Browse 75 tables and 23 figures spread through 245 pages and in-depth TOC on "High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) - Forecast to 2018"
hxxp://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html
Early buyers will receive 10% customization on reports.

This report studies the global high throughput screening (HTS) market over the forecast period of 2013 to 2018. The global HTS market was valued at an estimated $13,735.88 million in 2013 and is poised to grow at a CAGR of 7.4% from 2013 to 2018, to reach $19,626.54 million by 2018.

A number of factors such as technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in the HTS technology by organizations are driving the growth of the HTS market. Moreover, the presence of a large untapped market in emerging countries and the incessant rise in outsourced drug discovery services especially in China and India are the various growth opportunities in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors that are curbing the growth of this market.

The HTS market is broadly classified into five segments, namely, technology, products, applications, end users, and geography. In the applications segment, the target identification market held the largest share of 45% in 2013. The availability of large compound libraries and well-equipped HTS laboratories, and technological advancements are the major factors driving the growth of this market. However, the primary screening market is poised to grow at the highest CAGR. The availability of a large number of potential lead compounds, emergence of several new detection technologies, and availability of novel primary and stem cell phenotypes are the factors that are responsible for the growth of this market segment. The growth in the outsourcing of drug services, especially in the Asian region, is a major reason for the high growth of the HTS market. In the end-users market, the pharmaceuticals segment dominated the market in 2013, with a market share of around 45%. In the technology market, the label-free technology segment is expected to register the highest growth in the forecast period. Label-free technology offers the direct detection ability, which was not possible with cell-based assays. Furthermore, it helps in reducing drug failure due to toxicity and can be applied to a majority of drug classes.

The global HTS market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The large market share of the North American region is attributed to the increased investments by drug discovery firms for the promotion and advancement of technologies and increasing number of collaborations among companies and academia to develop and distribute innovative HTS products.

The major players in the HTS market include Agilent Technologies (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.), and Tecan group (Switzerland), among others.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: [phone]
Email: [e-mail]

[buywell2] 15/3/2015 12:18

HTS in the piece below is High Throughput Screening , Cyprotex offer this using their own unique IP and Tecan Robotics

Cyprotex also offer a large range of Cell-Based Assays , re above last two posts it will most likely be the use of human living brain cells that paves the way for a new range of Transporter Assays that the FDA will mandate








Cell-Based Assay Market worth $14.8 Billion by 2018

The “Cell-Based Assays Market by Application (Drug Discovery, ADMET), Product [(Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services)], End-user (Pharmaceutical, CRO) - Global Forecast to 2018” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and Rest of the World.



Browse 88 market data Tables and 20 Figures spread through 243 Pages and in-depth TOC on "Cell-Based Assays Market by Application (Drug Discovery, ADMET), Product [(Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services)], End-user (Pharmaceutical, CRO) - Global Forecast to 2018"
hxxp://www.marketsandmarkets.com/Market-Reports/cell-based-assays-market-119917269.html
Early buyers will receive 10% customization on reports.

This report studies the global cell-based assays market over the forecast period of 2013 to 2018.

The global by product market is poised to reach $14.8 billion by 2018, at a CAGR of 11.1%.The major market propellants for cell-based assays are benefits of cell-based assays over biochemical assays and animal models and public-private partnerships for drug discovery. The growth market is also driven by continuous innovations and developments in the market aimed at higher throughput. The opportunities for the growth of this market include developments in emerging markets such as Asia, introduction of technologically advanced products, and increase need of toxicity screening. However, factors such as intellectual property rights are restricting innovation in the market and hence hindering growth. The optimization of assay for cell-based assay is still a challenge while complexity of HTS assays and assay standardization and validation is still an unmet need. However, some revolutionary platforms like label-free technology, 3D assays, induced pluripotent stem cells are expected to gain traction in future.

This research report categorizes and analyzes the global market on the basis of products, applications, end-users and geography in the market. All these markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2011, 2012, 2013, and forecast to 2018. Based on the cell-based assay product type, consumables (assay kits, reagents, microplates, cell lines), detection and screening instruments, automation and high throughput screening instruments, software and services form the overall market. Under applications market for cell-based assay drug discovery, ADME studies, predictive toxicology and basic research are covered. The end-users market covers academic and government institutions, pharmaceutical and biotechnology companies, and contract research organizations.

North America accounted for the largest market share of the market, followed by Europe, in 2013. However, Asia presents significant opportunities for investors as the developed markets get saturated.

The major players included in this report are BD Biosciences (U.S.) , Danaher Corporation (U.S.), DiscoveRx (U.S.), EMD Millipore (Germany), GE Healthcare (U.K.), Life Technologies Corporation (U.S.), PerkinElmer (U.S.), and Promega Corporation (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304,Preston Road,
Suite 800, Dallas, TX 75252
Tel: [phone]
Email: [e-mail]

[p1nkfish] 14/3/2015 09:31

he is a good hire.
will add value and proves crx weight in the market simply by having attracted him.

[buywell2] 13/3/2015 12:54

I posted a couple of months back re Statins and other common used drugs and their bad effects.

Transporter Studies for Regulatory Submission

New regulatory guidelines for the investigation of drug interactions were released in 2012: The US Food and Drug Administration (FDA) published the draft guidance for comment in February, 2012. The final version of the European Medicines Agency (EMA) Guidelines on the Investigation of Drug Interactions came into effect on the 1st of January, 2013.

The Japanese Ministry of Health, Labour, and Welfare (MHLW) published the tentative guidance in January, 2014. The European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and The Japanese Ministry of Health, Labour, and Welfare (MHLW) require a variety of Drug Transporter studies be performed for any New Chemical/Molecular Entity (NCE/NME). Cyprotex will be able to help companies world-wide with performing these studies, interpreting the regulatory requirements, study design, and reporting. Cyprotex will soon be able to offer the broadest array of transporter assays commercially available to assist customers with meeting regulatory requirements.



With over 50% of the population now on Statins, anti-depressants , pain killers, sleeping pills and the like ....


Clearly there is a case for transporter assays to be made mandatory by the FDA for such drugs with ANY new drug up for approval.That they have not yet done so is somewhat of a surprise

However when they do .... there will also be some surprises of the not so good kind methinks .... which could well lead to some drugs getting withdrawn


So maybe not so much of a surprise then .... the delay thus far, I mean






Dr Elsby from AZ seems a good choice to get Cyprotex into the leading edge in this fairly new area of drug development

[mrphil] 12/3/2015 08:27

Thought that appointment sounded like good news, but the market seems to disagree!

[p1nkfish] 01/3/2015 11:09

Henderson hold here too which fits in with the eco system with CRX, SBS etc.I have all 3 as stakes now. Worth a listen.

[buywell2] 11/2/2015 10:47

90,000 VOL the other day = 900,000 in olde money


Pushed up the share price as has been stated , the number held by longer term investors has grown = reduced float


The buy now sell in 3 days brigade has departed hence to other stocks


Like I said it would be good to see another Institution buy a stake here of say 10% or a bit more .... perhaps as part of another acquisition

[p1nkfish] 11/2/2015 08:58

They are well embedded here contributing with all the big names:

hxxp://www.ddmore.eu/partners/people?order=field_partner_full_name&sort=asc

Do a browse around this. Good to be in the middle of it.

hxxp://www.ddmore.eu/content/project

[p1nkfish] 10/2/2015 21:28

With such a reduced float even a little interest can be rocket fuel.
Imagine what could happen if someone wanted to take 5-10% off the market.

No good looking back. It's in a much better position now and Baxter needs 120p to get his payout and I doubt he would be satisfied with just that.